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Abstract
Background: The prevalence of dyslipidemia in China was increased over the last several years. Studies have
shown that the activity of aBAT is related to the lipid metabolism. In this study, we analyzed blood lipid level in
tumor-free healthy Chinese adults in order to determine the role of aBAT in lipid metabolism.
Methods: We retrospectively analyzed the factors that affect the blood lipid level in 717 tumor-free healthy adults
who received blood lipid measurement and PET/CT scan by multivariate regression analysis. We also determined
the role of aBAT on lipid profile by case–control study.
Results: (1) Our results showed that 411 (57.3 %) subjects had dyslipidemia. The prevalence of the subjects with
hypercholesteremia, hypertriglyceridemia, low high-density lipoprotein cholesterol and high low-density lipoprotein
cholesterol was 9.5 %, 44.4 %, 30.8 % and 1.4 %, respectively. Multivariate logistic regression analysis with
dyslipidemia as the dependent variable showed that body mass index (BMI) and smoking are independent risk
factors for dyslipidemia (OR > 1, P < 0.05), while the presence of aBAT is the independent protective factor for
dyslipidemia (OR < 1, P < 0.05). (2) The incidence of aBAT was 1.81 %. Subjects with aBAT had significantly lower
serum triglyceride and higher serum high-density lipoprotein cholesterol than the subjects without aBAT. The
serum total cholesterol and low-density lipoprotein cholesterol were not significantly different between the
subjects with aBAT and those without aBAT.
Conclusions: Dyslipidemia is caused by multiple factors and the presence of aBAT is a protective factor for
dyslipidemia in healthy Chinese adults.
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Background
Cardiovascular disease is the primary cause of death in
most countries worldwide [1, 2], including China. Dys-
lipidemia is a major risk factor for atherosclerosis. Dys-
lipidemia is also the independent risk factor for
myocardial infarction [3] and ischemic stroke [4], and
therefore represents a serious threat to human health.
Due to the low dietary intake of fat and cholesterol, the
type of dyslipidemia (mainly hypertriglyceridemia and
low high-density lipoprotein cholesterol) in Chinese
adult is different from those in Western countries. More
importantly, evidence suggests that the prevalence of
dyslipidemia in China is significantly increased over the
past several years [2, 5].
Brown adipose tissue (BAT) is the main source of
non-trembling heat, and it plays an important role in
maintaining the body temperature and energy metabol-
ism balance. The mitochondrial inner membrane of
brown fat cells is rich in uncoupling protein 1 (UCP l),
which converts chemical energy into thermal energy
through the uncoupling of oxidative phosphorylation [6].
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It was previously believed that BAT exists only in the
fetal and infancy period of rodents and humans. How-
ever, recent PET/CT studies [7, 8] showed that BAT with
high capacity of 18F-fluorodeoxyglucose (18F-FDG, an
analogue of glucose which is used for PET/CT scan) up-
take also exists in adult humans, which is recognized as
active brown adipose tissue (aBAT). Studies have also
shown that the occurrence of aBAT is correlated with
age, gender, degree of obesity and outdoor temperature
when PET/CT scan was performed.
Most of the previous studies used experimental ani-
mals or patients with tumors to investigate the effect of
aBAT on lipid metabolism [9–11]. These studies showed
that aBAT plays an important role in clearing the trigly-
ceride in the blood. However, cancer patients may have
lipid abnormalities when treated with anticancer drugs
[12], such as Everolimus, Tamoxifen, Goserelin, which
increases the complexity to study the effect of aBAT on
lipid metabolism. In this study, we performed multivari-
ate regression analysis to identify the factors that con-
tribute to dyslipidemia in the tumor-free Chinese adults
to explore the role of aBAT in dyslipidemia.
Methods
Subjects
The subjects receiving 18F-FDG PET/CT scan due to ele-
vated tumor markers of unknown reasons, family history
of tumors, and suspected contact with carcinogen from
October 2010 to December 2015 were obtained from
our Medical Center. For the present analysis, the inclu-
sion criteria were as follows: 1) adult (older than
18 years), 2) no history of cancer, 3) receiving blood lipid
measurement at the same day when 18F-FDG PET/CT
scans were performed. The exclusion criteria were: 1)
subjects who had been diagnosed as dyslipidemia and
took oral lipid-lowering drugs, 2) subjects who took oral
β-receptor blockers, 3) subjects who took hormone
drugs (such as thyroid hormone, estrogen, steroids), 4)
subjects who had acute and chronic liver and kidney
dysfunction, 5) subjects who had disorders that may lead
to malabsorption (such as chronic atrophic gastritis, an-
orexia, etc.).
A total of 717 subjects met the inclusion criteria and
we recorded the gender, age, height, weight, body mass
index (BMI), smoking status (not including passive
smoking), alcohol (drinking at least once a week), fasting
plasma glucose concentrations, blood lipid levels (in-
cluding total cholesterol (TC), triglycerides (TG), high-
density lipoprotein cholesterol (HDL-C), low-density
lipoprotein cholesterol (LDL-C)), and the outdoor
temperature of the day when PET/CT scans were per-
formed. According to Chinese control of overweight and
obesity guidelines [13], subjects with BMI between 24
and 27.9 kg/m2 are considered overweight, and subjects
with BMI ≥ 28 kg/m2 are considered obese. According to
the American Diabetes Association guidelines [14], sub-
jects with the fasting plasma glucose concentration ≥
7.0 mmol/L or subjects who were previously diagnosed
with diabetes and are being treated are considered as
diabetic.
Blood lipid analysis and criteria for dyslipidemia
Blood samples (5 ml, obtained after minimal 8 h of fast-
ing) were collected before 18F-FDG PET/CT scan. The
concentrations of serum TC, TG, HDL-C and LDL-C
were measured by enzymatic methods using Hitachi
7600–120 automatic biochemical analyzer. Internal qual-
ity control was performed at the same time and all oper-
ations were in strict accordance with the instructions.
Subjects with at least one of the following criteria: serum
TC ≥ 6.22 mmol/L (240 mg/dl), serum TG ≥ 2.26 mmol/
L (200 mg/dl), serum HDL-C < 1.04 mmol/L (40 mg/dl),
and serum LDL-C ≥ 4.14 mmol/L (160 mg/dl) can be
considered as dyslipidemia. Factors, such as age, sex,
BMI, smoking, drinking, diabetes, and the presence of
aBAT that may have an impact on blood lipids were
analyzed.
PET/CT scan and definition of aBAT
PET/CT scan was performed using 18F-FDG (radio-
chemical purity > 95 %) as the imaging agent (Siemens
Biograph mCT (64) type PET/CT instrument). Before
PET/CT scan, the subjects underwent minimal 8 h of
fasting. Subjects with the fasting plasma glucose below
11.1 mmol/L were intravenously injected with 18F-FDG
at the average dose of 4.74 ± 0.93 MBq/kg. Following
45–60 min of rest in a quiet, warm and dark environ-
ment and urination, PET/CT scan was performed. Syngo
Ture D system was used for image reconstruction, which
forms cross-sectional, coronal, sagittal tomographic
image and three-dimensional projection image.
According to the literature [7], tissues that are located at
the neck and supraclavicular region, mediastinum and
both armpits, on both sides of the spine, kidney and other
peripheral regions are considered as aBAT if CT value is
at the adipose tissue density (CT value of −250 ~ −50HU),
the diameter is larger than 4 mm, and maximum stan-
dardized uptake value of 18F-FDG in PET imagings is at
least 2 (SUVmax ≥ 2) (Fig. 1). Active BAT was detected in
13 subjects with an occurrence of 1.8 % (13/717). To re-
duce the impact of sampling error and to observe the ef-
fect of aBAT on blood lipids more intuitively, 1:3 ratio
between the number of the subjects in aBAT group and
that in control group was used because 1:3 or 1:4 ratio
can obtain higher statistics power [15]. The gender, age,
BMI, fasting blood glucose and the outdoor temperature
were not significantly different between the two groups. In
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order to reduce subjective bias, lipid profiles were not
considered when the control group was selected.
One subject (34 years old) was a female with a BMI of
20.2 kg/m2 and fasting blood glucose of 5.0 mmol/L. Due
to a family history of tumor, the subject requested 18F-
FDG PET/CT whole body scan. The outdoor temperature
at the day when the scan was performed was 8 °C. Active
BAT was distributed on both sides of neck, armpits,
supraclavicular region, mediastinum, and the spine.
Statistical analysis
Statistical analyses were performed using SPSS 23.0 soft-
ware. Measurement data were expressed as mean ±
standard deviation (± s). Kolmogorov-Smirnov test was
first performed to determine whether the measurement
data follow a normal distribution. The normally distrib-
uted data were compared using independent t-test. The
non-normally distributed data were compared using
Mann–Whitney u rank sum test. The percentage data
were compared using χ2 test. When the theoretical fre-
quency in a linked list was less than 1, Fisher exact test
was used. Logistic regression analysis with two categor-
ical variables was performed to determine the factors
that can affect dyslipidemia. The regression coefficient,
odds ratio (OR) and 95 % confidence intervals were cal-
culated. P <0.05 (two-sided) was considered statistically
significant.
Results
Characteristics of the subjects
The general characteristics of studied subjects are listed
in Table 1.
Univariate and multivariate logistic regression analysis of
dyslipidemia
Among 717 subjects included in this study, 411 subjects
(57.3 %) had dyslipidemia. The average serum TC, TG,
HDL-C, and LDL-C levels were 5.20 ± 1.08 mmol/L,
3.57 ± 2.55 mmol/L, 1.08 ± 0.25 mmol/L, and 2.52 ±
0.69 mmol/L, respectively. The percentages of the sub-
jects with hypercholesteremia, hypertriglyceridemia, low
HDL-C and high LDL-C were 19.5 %, 44.4 %, 30.8 %
and 1.4 %, respectively. Lipid level was designated as
variable (abnormal y = 1, normal y = 0), and univariate
Fig. 1 (a and b) Distribution of aBAT in one subject included in this study
Table 1 Baseline characteristics of studied subjects
Parameters Subjects
(n = 717)
Age (years) 49.8 ± 9.7
Male (%) 66.4
BMI (kg/m2) 24.8 ± 3.2
Normal weight (%) 39.8
Overweight (%) 45.6
Obesity (%) 14.6
Current Smoker (%) 38.4
Current Drinker (%) 34.3
Diabetes (%) 12.7
Outdoor temperature (°C) 21.6 ± 9.1 °C
aBAT (%) 1.81
BMI body mass index, aBAT active brown adipose tissue
Normal weight: BMI < 24 kg/m2, Overweight: BMI between 24 and 27.9 kg/m2,
Obesity: BMI ≥ 28 kg/m2
Outdoor temperature was the outside temperature of the day when PET/CT
scan was performed
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analysis was performed to identify factors (age, sex, BMI,
smoking, drinking, diabetes, aBAT) that may affect dys-
lipidemia (Table 2). The statistically significant factors in
univariate analysis were further analyzed by multivariate
logistic regression analysis. These results showed that
high BMI and smoking were independent risk factors for
dyslipidemia (OR > 1, P < 0.05), and the presence of
aBAT was an independent protective factor for dyslipid-
emia (OR < 1, P < 0.05) (Table 3).
Comparison of the blood lipids between the aBAT group
and the control group
The 13 subjects with the presence of aBAT were defined
as aBAT group. The aBAT-negative subjects with similar
age, gender ratio, BMI, fasting glucose level and outdoor
temperature were selected as control group (Table 4).
The levels of TC, TG, HDL-C and LDL-C were com-
pared between the two groups. The results showed that
serum TG level in aBAT group was significantly lower
than that in the control group (1.41 ± 0.54 vs. 2.70 ±
2.88 mmol/L, P = 0.024). The level of serum HDL-C in
the aBAT group was significantly higher than that in the
control group (1.46 ± 0.26 vs. 1.26 ± 0.30 mmol/L, P =
0.032). The levels of serum TC and LDL-C in aBAT
group were lower (but not significantly) than those in
the control group (TC: 4.79 ± 0.93 vs. 4.96 ± 1.0 mmol/L
and LDL-C: 2.28 ± 0.61 vs. 2.36 ± 0.52 mmol/L) (P =
0.587 and P = 0.620, respectively) (Fig. 2A-2D). The ratio
TC/HDL-C in the aBAT group was significantly lower
than that in the control group (3.36 ± 0.78 vs. 4.19 ±
1.40 mmol/L, P = 0.047).
Discussion
Dyslipidemia often includes hypercholesteremia, hypertri-
glyceridemia, high LDL-C and low HDL-C [16]. The types
of dyslipidemia in Asian countries including China are
mainly manifested as hypertriglyceridemia and low HDL-
C, which is different from those in the United States and
Europe [2, 5, 17]. In this study, the occurrence of dyslipid-
emia was 57.3 %, with the incidence of hypertriglyc-
eridemia and low HDL-C at 44.4 % and 30.8 %,
respectively, which is slightly higher than the recent epi-
demiological findings [5], but basically reflects the abnor-
mal status of blood lipids in this region. PET/CT scan
showed that the occurrence of aBAT in 717 subjects was
1.8 %, which was similar to that in other neighboring cities
with similar latitude. Zhang et al. [18] showed that aBAT
occurrence was 1.58 % in 31,088 subjects receiving PET/
CT scan.
Univariate analysis showed that dyslipidemia was cor-
related with multiple factors including gender, BMI
(overweight and obesity), smoking, alcohol consumption,
and diabetes, suggesting that dyslipidemia is not caused
by a single factor, but rather caused by multiple factors.
Furthermore, multivariate regression analysis showed
that BMI and smoking are independent risk factors for
dyslipidemia, which is consistent with the results of pre-
vious studies [19, 20]. More importantly, we found that
aBAT is a protective factor for dyslipidemia in the
healthy Chinese adults (OR = 0.076, P < 0.05).
There were relatively few clinical studies examining
the effect of aBAT on lipid metabolism. Zhang et al. [21]
showed that aBAT was positive in 62 out of 3329 sub-
jects receiving PET/CT scans. Furthermore, HDL-C is






Age (years) 49.8 ± 9.4 49.9 ± 10.1 0.942
Male (%) 74.2 55.9 <0.001*
BMI (kg/m2) 25.5 ± 2.9 23.8 ± 3.2 <0.001*
Normal weight (%) 30.7 52.0 <0.001*
Overweight (%) 49.9 39.9
Obesity (%) 19.4 8.1
Current Smoker (%) 45.7 28.4 <0.001*
Current Drinker (%) 38.2 29.1 0.011*
Diabetes (%) 15.3 9.2 0.014*
aBAT (%) 0.2 3.9 <0.001*
BMI body mass index, aBAT active brown adipose tissue
Normal weight: BMI < 24 kg/m2, Overweight: BMI between 24 and 27.9 kg/m2,
Obesity: BMI ≥ 28 kg/m2
*Significant difference
Table 3 Multivariate and Logistic regression analysis of factors
contributing to dyslipidemia
Variables Regression coefficient OR 95 % CI P value
Gender −0.271 0.762 0.497 ~ 1.170 0.215
BMI 0.162 1.175 1.112 ~ 1.234 <0.001*
Smoke 0.521 1.684 1.134 ~ 2.501 0.010*
Drink −0.158 0.854 0.577 ~ 1.265 0.432
Diabetes 0.236 1.266 0.769 ~ 2.085 0.353
aBAT −2.575 0.076 0.010 ~ 0.610 0.015*
OR odds ratio, CI confidence index, aBAT active brown adipose tissue
*Significant difference






Age (years) 41.9 ± 6.5 41.8 ± 6.4 0.950
Male /Female 5/8 15/24
BMI (kg/m2) 22.9 ± 2.6 23.7 ± 2.3 0.286
Fasting plasma glucose (mmol/L) 5.08 ± 0.59 5.45 ± 0.60 0.062
Outdoor temperature (°C) 12.5 ± 7.1 12.7 ± 7.3 0.947
aBAT active brown adipose tissue, BMI body mass index
Outdoor temperature was the outside temperature of the day when PET/CT
scan was performed
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higher, while TC/HDL-C is lower in the subjects with
positive aBAT compared to the subjects with negative
aBAT. However, in that study, BMI was significantly dif-
ferent between aBAT-positive group and the aBAT-
negative group. Studies have demonstrated that BAT
level and activity were negatively correlated with BMI
[7]. Van Marken et al. [22] showed that subjects with
BMI of 38.7 kg/m2 did not exhibit BAT imaging even
the subjects were exposed to a cold environment. In a
retrospective study of 5,907 cases of cancer patients
(Caucasian), Ozguven et al. [11] showed that 25 subjects
were aBAT-positive with a positive rate of 0.4 %. Based
on the 1:3 ratio between the number of subjects in
aBAT-positive group and that in the control group, the
study showed that blood TC and LDL-C in the aBAT-
positive group were significantly lower than that in the
control group. However, blood TG and HDL-C were not
significant different between the two groups. These find-
ings suggested that different population (e.g., physical
exam group, tumor group), or population in different re-
gions had different types of dyslipidemia (Chinese popu-
lation mainly had high TG and low HDL-C, while
Europeans and Americans mainly had high TC and high
LDL-C). The effect of aBAT on different lipid compo-
nents is different. The results of this study were partially
consistent with previous studies [21]. However, we also
showed that serum TG level in aBAT group was lower
than that of the control group, which is different from
other studies [11, 21].
Animal studies [10, 23] have indicated that increasing
BAT activity can increase TG clearance in plasma. Bar-
telt et al. [23] found that increasing the BAT activity in
vivo in mice by cold stimulation can modulate the clear-
ance of triglyceride-rich lipoproteins (TRLs), resulting in
decreased levels of serum TG and increased levels of
HDL-C. This process is dependent on the increased vas-
cular endothelial permeability to lipoprotein, local lipo-
protein lipase activity and transmembrane receptor
Fig. 2 Comparison of the blood lipid level between aBAT and control groups. Comparison of blood TG between aBAT and control groups (a);
Comparison of blood HDL-C between aBAT and control groups (b); Comparison of blood TC between aBAT and control groups (c); Comparison
of blood LDL-C between aBAT and control groups (d)
Shao et al. Lipids in Health and Disease  (2016) 15:138 Page 5 of 7
CD36. Khedoe et al. [10] found that BAT takes up
plasma TG preferentially by means of lipolysis-mediated
uptake of fatty acids. These animal studies revealed the
mechanisms of low TG and high HDL-C in the aBAT
group in this study. These studies also demonstrated the
important value of aBAT in lipid metabolism.
Statins are the most widely used drugs to treat hyper-
lipidemia and can reduce the cholesterol concentration
by 30 % [24]. However, statin treatment only prevents
25 % to 45 % of all cardiovascular events [25]. One po-
tential factor limiting further reduction in cardiovascular
events is the residual elevation in serum TG levels [26].
aBAT was demonstrated as a key player in triglyceride
metabolism in our study. Furthermore, aBAT decreases
cholesterol levels as well [9, 11]. Our results provide a
new therapeutic target to prevent hyperlipidemia and
atherosclerosis.
Limitations
The study was not a large-scale multicenter epidemio-
logical survey and the occurrence of dyslipidemia only
reflects the area that we studied. The occurrence of
aBAT is similar to other cities at the same latitude [18].
However, only 717 subjects met the inclusion criteria
and there were only 13 aBAT-positive subjects. Although
we have strict control by setting the standard and blind
selection (concealing the status of subjects in the control
group and hyperlipidemia during selection), subjective
factors leading to the selection bias cannot be com-
pletely avoided.
Conclusions
Dyslipidemia is not caused by a single factor. In contrast,
it is the result of multiple factors. This study demonstrated
that obesity and smoking are risk factors for dyslipidemia,
and a healthy lifestyle is the basis for the prevention and
control of dyslipidemia. More importantly, this study
demonstrated that aBAT has a protective effect against
dyslipidemia, which is mainly manifested by lower levels
of serum TG and TC/HDL-C, and higher HDL-C level in
the aBAT group. Clinical studies have verified that aBAT
can increase plasma TG clearance, indicating the value of
aBAT the prevention of dyslipidemia and cardiovascular
and cerebrovascular diseases. At the same time, it provides
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